Dexamethasone administered in vivo to immune-deficient mice resulted in a significant up-regulation of the MUC1 expression levels in the tumor cells and a greater sensitivity to complement-mediated cytotoxicity, suggesting that dexamethasone can be used as an adjuvant for immune-targeted against MUC1 therapy [166]. The gene discussed is MUC1; the disease is neoplasm.